Pacific Biosciences of California, Inc. (PACB) SEC filings

PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$1.96−0.01 (-0.51%)

Close on Nov 13, 2026Market cap $609.23MP/E –Yield 0.00%

SEC filings

40 of Pacific Biosciences of California's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 3, 2026	Nov 4, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 8, 2026	Jul 9, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 4, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 6, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 5, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 25, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Jan 28, 2026	Feb 3, 2026	SEC EDGAR
Current report	8-K	Jan 30, 2026	Feb 2, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 4, 2025	Jun 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 4, 2025	Apr 23, 2025	SEC EDGAR
Current report	8-K	Apr 9, 2025	Apr 9, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 27, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 17, 2025	SEC EDGAR
Current report	8-K	Mar 7, 2025	Mar 13, 2025	SEC EDGAR
Current report	8-K	Feb 13, 2025	Feb 13, 2025	SEC EDGAR
Current report	8-K	Jan 24, 2025	Jan 30, 2025	SEC EDGAR
Current report	8-K	Jan 14, 2025	Jan 14, 2025	SEC EDGAR
Current report	8-K	Dec 11, 2024	Dec 13, 2024	SEC EDGAR
Current report	8-K	Dec 5, 2024	Dec 6, 2024	SEC EDGAR
Current report	8-K	Nov 21, 2024	Nov 22, 2024	SEC EDGAR
Current report	8-K	Nov 11, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 5, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 9, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Pacific Biosciences of California's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PACB.

Compare: PACB vs QTRX · PACB vs CTKB · PACB vs TXG · PACB vs HBIO · PACB vs BNGO

Revenue growth4.4% · median 5.5%

Gross margin34.4% · median 54.7%

Operating margin-81.3% · median -21.1%

Net margin-81.3% · median -39.1%

Company	Revenue	Growth
TXG	$618.58M	-3.6%
CTKB	$207.65M	+5.5%
PACB	$161.39M	+4.4%
QTRX	$148.15M	+13.8%
HBIO	$89.41M	+2.3%
BNGO	$31.09M	+8.2%

Company

Next earnings (est.): Feb 11, 2027, after close
Exchange: Nasdaq
Industry: Laboratory Analytical Instruments
Fiscal year ends: December 31
Employees: 485
Held by institutions: 61.5%
Auditor: Ernst & Young LLP
SEC CIK: 1299130

Advertisement
300 × 250

See a number that looks wrong?